Accordingly, multiple studies have been conducted focusing on the development of new PTP1B inhibitors for the treatment of T2DM, obesity, and cancer, but to the authors’ knowledge there are no review articles published on this subject. This evidence concerns the gene PTPN1 and obesity due to melanocortin 4 receptor deficiency.